| Literature DB >> 26508743 |
Fenglei Wang1, Jusheng Zheng1, Bo Yang1, Jiajing Jiang1, Yuanqing Fu1, Duo Li1.
Abstract
BACKGROUND: Vegetarian diets exclude all animal flesh and are being widely adopted by an increasing number of people; however, effects on blood lipid concentrations remain unclear. This meta-analysis aimed to quantitatively assess the overall effects of vegetarian diets on blood lipids. METHODS ANDEntities:
Keywords: cholesterol; diet; lipoprotein lipids; triglyceride; vegetarian
Mesh:
Substances:
Year: 2015 PMID: 26508743 PMCID: PMC4845138 DOI: 10.1161/JAHA.115.002408
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Flow diagram of selection of relevant articles.
Characteristics of Studies Included in the Meta‐Analysis: Participants, Interventions, and Comparators
| Study | Country | No. (F/M) | Mean BMI, kg/m2 | Mean Age, Year | Healthy Status | Lipid‐Lowering Medication (E/C) | Intervention | Control |
|---|---|---|---|---|---|---|---|---|
| Cooper et al, 1982 | US | 15 (5/10) | NR | 28.0 | Healthy subjects | None | Lactovegetarian | Omnivorous |
| Kestin et al, 1989 | Australia | 26 (0/26) | 25.5 | 44.0 | NR | None | Lacto‐ovovegetarian | Omnivorous |
| Ling et al, 1992 | Finland | 18 (14/4) | 26.6 | 42.8 | Healthy participants and patients for unrelated conditions | NR | Vegan | Omnivorous |
| Nicholson et al, 1999 | US | 11 (5/6) | NR | 54.3 | With NIDDM | 4 (3/1) | Vegan | Omnivorous |
| Barnard et al, 2000 | US | 35 (35/0) | 25.5 | 36.1 | Healthy premenopausal women | None | Vegan | Omnivorous |
| Agren et al, 2001 | Finland | 29 (28/1) | 24.3 | 50.8 | With rheumatoid arthritis | None | Vegan | Omnivorous |
| Burke et al, 2007 | US | 176 (153/23) | 34.0 | 44.0 | Overweight and obese adults | None | Lacto‐ovovegetarian | Omnivorous |
| Elkan et al, 2008 | Sweden | 58 (52/6) | 24.0 | 50.3 | With rheumatoid arthritis | None | Vegan | Omnivorous |
| Barnard et al, 2009 | US | 99 (60/39) | 34.9 | 55.6 | With type 2 diabetes | 54 (27/27) | Vegan | Omnivorous |
| Kahleova et al, 2011 | Czech | 74 (39/35) | 35.0 | 56.2 | With type 2 diabetes | 38 (22/16) | Lactovegetarian | Omnivorous |
| Mishra et al, 2013 | US | 291 (241/50) | 35.0 | 45.2 | With BMI ≥25 and/or a previous diagnosis of type 2 diabetes | NR | Vegan | Omnivorous |
BMI indicates body mass index; E/C, experiment diet group/control diet group; F, female; M, male; NR, not reported.
All control diets adopted in these studies were defined as an omnivorous diet because they contained meat and dairy products and plant‐derived foods.
Characteristics of Studies Included in the Meta‐Analysis: Outcomes and Study Design
| Study | Baseline TC, mmol/L (E/C) | Baseline LDL‐C, mmol/L (E/C) | Baseline HDL‐C, mmol/L (E/C) | Baseline TG, mmol/L (E/C) | Duration | Outcome Analysis | Design |
|---|---|---|---|---|---|---|---|
| Cooper et al, 1982 | 4.1 | — | — | 0.7 | 3 weeks | PP | CO |
| Kestin et al, 1989 | 6.1 | 4.1 | 1.5 | 1.3 | 6 weeks | PP | CO |
| Ling et al, 1992 | (5.6/5.5) | (3.7/3.6) | (1.3/1.3) | (1.3/1.0) | 4 weeks | PP | PL |
| Nicholson et al, 1999 | (5.3/5.6) | — | (1.2/1.1) | (2.1/2.3) | 12 weeks | PP | PL |
| Barnard et al, 2000 | 4.2 | 2.5 | 1.3 | 0.9 | 2 months | PP | CO |
| Agren et al, 2001 | (4.6/5.2) | (3.0/3.5) | (1.2/1.2) | (1.0/1.0) | 3 months | PP | PL |
| Burke et al, 2007 | (5.3/5.3) | — | — | (1.5/1.5) | 18 months | ITT | PL |
| Elkan et al, 2008 | — | — | (1.4/1.3) | (1.1/1.1) | 12 months | PP | PL |
| Barnard et al, 2009 | (4.8/5.2) | (2.7/3.0) | (1.4/1.3) | (1.7/1.8) | 74 weeks | ITT | PL |
| Kahleova et al, 2011 | (4.4/4.2) | (2.5/2.6) | (1.1/1.1) | (2.1/2.1) | 12 weeks | ITT | PL |
| Mishra et al, 2013 | (4.8/4.9) | (2.8/2.8) | (1.4/1.5) | (1.4/1.4) | 18 weeks | ITT | PL |
CO indicates crossover; E/C, experiment diet group/control diet group; HDL‐C, high‐density lipoprotein cholesterol; ITT, intention to treat; LDL‐C, low‐density lipoprotein cholesterol; PL, parallel; PP, per protocol; TC, total cholesterol; TG, triglyceride.
Figure 2Effects of vegetarian diets on (A) TC and (B) LDL‐C concentrations. The meta‐analysis used the WMD in the random‐effects model. Horizontal lines denote 95% CI. A diamond represents the overall estimated effect. LDL‐C indicates low‐density lipoprotein cholesterol; TC, total cholesterol; WMD, weighted mean difference.
Figure 3Effects of vegetarian diets on (A) HDL‐C and (B) TG concentrations. The meta‐analysis used the WMD in the random‐effects model. Horizontal lines denote 95% CI. A diamond represents the overall estimated effect. HDL‐C indicates high‐density lipoprotein cholesterol; TG, triglyceride; WMD, weighted mean difference.
Figure 4Effects of vegetarian diets on non–high‐density lipoprotein cholesterol concentrations. The meta‐analysis used the WMD in the random‐effects model. Horizontal lines denote 95% CI. A diamond represents the overall estimated effect. WMD, weighted mean difference.
Subgroup and Meta‐Regression Analyses for TC and LDL‐C Concentrations
| Subgroup Factors | TC | LDL‐C | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Trials | Pooled Effect (95% CI) mmol/L | I2 (%) |
|
| No. of Trials | Pooled Effect (95% CI) mmol/L | I2 (%) |
|
| |
| Overall analyses | 10 | −0.36 (−0.55 to −0.17) | 53.5 | 0.02 | 7 | −0.34 (−0.57 to −0.11) | 72.4 | <0.001 | ||
| Overall analyses | 10 | −0.32 (−0.43 to −0.20) | 53.5 | 0.02 | 7 | −0.30 (−0.41 to −0.19) | 72.4 | <0.001 | ||
| Continent | 0.24 | 0.39 | ||||||||
| Oceania | 1 | −0.61 (−1.14 to −0.08) | — | — | 1 | −0.61 (−1.11 to −0.11) | — | — | ||
| Europe | 3 | −0.58 (−1.20 to 0.04) | 79.8 | 0.01 | 3 | −0.46 (−1.04 to 0.11) | 87.9 | <0.001 | ||
| North America | 6 | −0.25 (−0.40 to −0.09) | 13.0 | 0.33 | 3 | −0.20 (−0.35 to −0.05) | 0.0 | 0.72 | ||
| Age, y | 0.96 | 0.79 | ||||||||
| <50 | 6 | −0.33 (−0.53 to −0.13) | 35.1 | 0.17 | 4 | −0.30 (−0.48 to −0.11) | 15.1 | 0.32 | ||
| ≥50 | 4 | −0.37 (−0.80 to 0.05) | 73.5 | 0.01 | 3 | −0.30 (−0.78 to 0.18) | 88.8 | <0.001 | ||
| BMI, kg/m2 | 0.01 | 0.01 | ||||||||
| 18.5 to 25 | 1 | −0.94 (−1.33 to −0.55) | — | — | 1 | −0.74 (−0.68 to −0.16) | — | — | ||
| 25 to 30 | 3 | −0.58 (−0.89 to −0.27) | 0 | 0.92 | 3 | −0.42 (−0.68 to −0.16) | 0 | 0.46 | ||
| ≥30 | 4 | −0.16 (−0.30 to −0.01) | 0 | 0.85 | 3 | −0.13 (−0.27 to 0.01) | 0 | 0.62 | ||
| Health status | 0.08 | 0.44 | ||||||||
| Healthy | 2 | −0.53 (−0.82 to −0.23) | 0 | 0.92 | 1 | −0.30 (−0.62 to 0.02) | — | — | ||
| High CVD risk | 5 | −0.15 (−0.30 to −0.01) | 0 | 0.93 | 3 | −0.13 (−0.27 to 0.01) | 0.0 | 0.62 | ||
| Lipid‐lowering medication | 0.20 | 0.19 | ||||||||
| Some | 3 | −0.17 (−0.39 to 0.06) | 0 | 0.95 | 2 | −0.06 (−0.26 to 0.14) | 0 | 0.79 | ||
| None | 5 | −0.51 (−0.84 to −0.18) | 70.9 | 0.01 | 2 | −0.40 (−0.68 to −0.11) | 4.6 | 0.31 | ||
| Intervention | 0.59 | 0.23 | ||||||||
| Lactovegetarian | 2 | −0.30 (−0.63 to 0.02) | 39.6 | 0.20 | 1 | −0.04 (−0.28 to 0.20) | — | — | ||
| Lacto‐ovovegetarian | 2 | −0.28 (−0.83 to 0.27) | 70.1 | 0.07 | 1 | −0.61 (−1.11 to −0.11) | — | — | ||
| Vegan | 6 | −0.44 (−0.73 to −0.14) | 60.1 | 0.03 | 5 | −0.37 (−0.65 to −0.09) | 73.3 | 0.01 | ||
| Duration, months | 0.64 | 0.92 | ||||||||
| <3 | 6 | −0.38 (−0.57 to −0.19) | 0 | 0.46 | 4 | −0.30 (−0.59 to −0.01) | 50.2 | 0.11 | ||
| ≥3 | 4 | −0.33 (−0.67 to 0.02) | 78.5 | 0.003 | 3 | −0.35 (−075 to 0.05) | 85.9 | 0.001 | ||
| Design | 0.26 | 0.68 | ||||||||
| Crossover | 3 | −0.55 (−0.80 to −0.29) | 0 | 0.96 | 2 | −0.40 (−0.68 to −0.11) | 4.6 | 0.31 | ||
| Parallel | 7 | −0.29 (−0.53 to −0.05) | 60.8 | 0.02 | 5 | −0.31 (−0.61 to −0.01) | 80.1 | <0.001 | ||
| Analysis | 0.01 | 0.02 | ||||||||
| PP | 6 | −0.64 (−0.85 to −0.43) | 0 | 0.50 | 4 | −0.57 (−0.82 to −0.33) | 35.3 | 0.20 | ||
| ITT | 4 | −0.16 (−0.30 to −0.01) | 0 | 0.85 | 3 | −0.13 (−0.27 to 0.01) | 0 | 0.62 | ||
| Publication year | 0.45 | 0.29 | ||||||||
| Before 2000 | 4 | −0.52 (−0.83 to −0.21) | 0 | 0.74 | 2 | −0.64 (−1.08 to −0.20) | 0 | 0.80 | ||
| 2000 or later | 6 | −0.32 (−0.56 to −0.09) | 69.0 | 0.01 | 5 | −0.28 (−0.54 to −0.02) | 79.1 | <0.001 | ||
BMI indicates body mass index; CVD, cardiovascular disease; ITT, intention to treat; LDL‐C, low‐density lipoprotein cholesterol; PP, per protocol; TC, total cholesterol.
P for heterogeneity
P for meta–regression analysis.
Results from fixed‐effect analysis.
Subgroup and Meta–Regression Analyses for HDL‐C and TG Concentrations
| Subgroup Factors | HDL‐C | TG | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Trials | Pooled Effect (95% CI) mmol/L | I2 (%) |
|
| No. of Trials | Pooled Effect (95% CI) mmol/L | I2 (%) |
|
| |
| Overall analyses | 9 | −0.10 (−0.14 to −0.06) | 0 | 0.58 | 11 | 0.04 (−0.05 to 0.13) | 19.9 | 0.25 | ||
| Overall analyses | 9 | −0.10 (−0.14 to −0.06) | 0 | 0.58 | 11 | 0.05 (−0.03 to 0.13) | 19.9 | 0.25 | ||
| Continent | 0.72 | 0.09 | ||||||||
| Oceania | 1 | −0.09 (−0.25 to 0.07) | — | — | 1 | 0.26 (0.01 to 0.51) | — | — | ||
| Europe | 4 | −0.11 (−0.17 to −0.05) | 0 | 0.45 | 4 | −0.12 (−0.27 to 0.04) | 0 | 0.67 | ||
| North America | 4 | −0.09 (−0.18 to −0.01) | 21.0 | 0.28 | 6 | 0.08 (−0.01 to 0.18) | 0 | 0.68 | ||
| Age, y | 0.97 | 0.08 | ||||||||
| <50 | 4 | −0.10 (−0.17 to −0.03) | 0 | 0.57 | 6 | 0.09 (−0.03 to 0.20) | 35.4 | 0.17 | ||
| ≥50 | 5 | −0.10 (−0.16 to −0.03) | 12.1 | 0.34 | 5 | −0.09 (−0.26 to 0.07) | 0 | 0.92 | ||
| BMI, kg/m2 | 0.82 | 0.72 | ||||||||
| 18.5 to 25 | 2 | −0.08 (−0.24 to 0.07) | 57.9 | 0.12 | 2 | −0.06 (−0.26 to 0.13) | 0 | 0.58 | ||
| 25 to 30 | 3 | −0.14 (−0.24 to −0.04) | 0 | 0.58 | 3 | 0.08 (−0.20 to 0.36) | 68.1 | 0.04 | ||
| ≥30 | 3 | −0.09 (−0.14 to −0.03) | 1.6 | 0.36 | 4 | 0.06 (−0.07 to 0.18) | 2.6 | 0.38 | ||
| Health status | 0.29 | 0.33 | ||||||||
| Healthy | 1 | −0.20 (−0.36 to −0.04) | — | — | 2 | 0.08 (−0.10 to 0.27) | 33.0 | 0.22 | ||
| High CVD risk | 4 | −0.09 (−0.15 to −0.04) | 0 | 0.49 | 5 | 0.06 (−0.06 to 0.18) | 0 | 0.54 | ||
| Lipid‐lowering medication | 0.99 | 0.20 | ||||||||
| Some | 3 | −0.10 (−0.18 to −0.03) | 5.6 | 0.35 | 3 | −0.16 (−0.46 to 0.14) | 0 | 0.85 | ||
| None | 3 | −0.10 (−0.21 to 0.02) | 38.9 | 0.20 | 6 | 0.07 (−0.04 to 0.17) | 15.0 | 0.32 | ||
| Intervention | 0.76 | 0.85 | ||||||||
| Lactovegetarian | 1 | −0.12 (−0.20 to −0.04) | — | — | 2 | −0.04 (−0.22 to 0.13) | 0 | 0.53 | ||
| Lacto‐ovovegetarian | 1 | −0.09 (−0.25 to 0.07) | — | — | 2 | 0.15 (−0.04 to 0.35) | 28.2 | 0.24 | ||
| Vegan | 7 | −0.09 (−0.15 to −0.03) | 2.8 | 0.40 | 7 | 0.02 (−0.12 to 0.15) | 27.2 | 0.22 | ||
| Duration, months | 0.20 | 0.81 | ||||||||
| <3 | 5 | −0.13 (−0.19 to −0.07) | 0 | 0.86 | 6 | 0.04 (−0.13 to 0.21) | 43.7 | 0.11 | ||
| ≥3 | 4 | −0.07 (−0.13 to 0.00) | 9.6 | 0.34 | 5 | 0.04 (−0.07 to 0.15) | 0 | 0.47 | ||
| Design | 0.39 | 0.17 | ||||||||
| Parallel | 7 | −0.09 (−0.14 to −0.04) | 0 | 0.57 | 8 | 0.00 (−0.10 to 0.10) | 3.0 | 0.41 | ||
| Crossover | 2 | −0.15 (−0.26 to −0.04) | 0 | 0.34 | 3 | 0.13 (−0.03 to 0.29) | 32.4 | 0.23 | ||
| Analysis | 0.54 | 0.99 | ||||||||
| PP | 6 | −0.12 (−0.19 to −0.05) | 0 | 0.53 | 7 | 0.03 (−0.10 to 0.17) | 35.9 | 0.15 | ||
| ITT | 3 | −0.09 (−0.14 to −0.03) | 1.6 | 0.36 | 4 | 0.06 (−0.07 to 0.18) | 2.6 | 0.38 | ||
| Publication year | 0.89 | 0.98 | ||||||||
| Before 2000 | 3 | −0.11 (−0.23 to 0.02) | 0 | 0.85 | 4 | 0.02 (−0.24 to 0.27) | 53.3 | 0.09 | ||
| 2000 or later | 6 | −0.10 (−0.15 to −0.04) | 19.7 | 0.28 | 7 | 0.05 (−0.04 to 0.15) | 0.7 | 0.42 | ||
BMI indicates body mass index; CVD, cardiovascular disease; HDL‐C, high‐density lipoprotein cholesterol; ITT, intention to treat; PP, per protocol; TG, triglyceride.
P for heterogeneity.
P for meta–regression analysis.
Results from fixed‐effect analysis.
Subgroup and Meta–Regression Analyses for Non–HDL‐C Concentrations
| Subgroup Factors | Non‐HDL‐C | ||||
|---|---|---|---|---|---|
| No. of Trials | Pooled Effect (95% CI) mmol/L | I2 (%) |
|
| |
| Overall analyses | 8 | −0.30 (−0.50 to −0.10) | 54.8 | 0.03 | |
| Overall analyses | 8 | −0.25 (−0.37 to −0.13) | 54.8 | 0.03 | |
| Continent | 0.35 | ||||
| Oceania | 1 | −0.52 (−0.99 to −0.05) | — | — | |
| Europe | 3 | −0.46 (−1.05 to 0.14) | 82.4 | 0.003 | |
| North America | 4 | −0.18 (−0.33 to −0.03) | 0 | 0.68 | |
| Age, y | 0.83 | ||||
| <50 | 4 | −0.26 (−0.44 to −0.08) | 9.8 | 0.34 | |
| ≥50 | 4 | −0.27 (−0.66 to 0.12) | 75.3 | 0.01 | |
| BMI, kg/m2 | 0.01 | ||||
| 18.5 to 25 | 1 | −0.78 (−1.13 to −0.43) | — | — | |
| 25 to 30 | 3 | −0.42 (−0.69 to −0.15) | 0 | 0.74 | |
| ≥30 | 4 | −0.12 (−0.26 to 0.02) | 0 | 0.79 | |
| Health status | 0.32 | ||||
| Healthy | 1 | −0.34 (−0.69 to 0.01) | — | — | |
| High CVD risk | 4 | −0.11 (−0.26 to 0.03) | 0 | 0.84 | |
| Lipid‐lowering medication | 0.08 | ||||
| Some | 3 | −0.09 (−0.29 to 0.11) | 0 | 0.69 | |
| None | 3 | −0.55 (−0.83 to −0.28) | 35.5 | 0.21 | |
| Intervention | 0.47 | ||||
| Lactovegetarian | 1 | −0.05 (−0.31 to 0.21) | — | — | |
| Lacto‐ovovegetarian | 1 | −0.52 (−0.99 to −0.05) | — | — | |
| Vegan | 6 | −0.33 (−0.58 to −0.08) | 57.4 | 0.04 | |
| Duration, months | 0.72 | ||||
| <3 | 5 | −0.24 (−0.47 to −0.01) | 21.4 | 0.28 | |
| ≥3 | 3 | −0.35 (−0.74 to 0.03) | 80.3 | 0.01 | |
| Design | 0.56 | ||||
| Crossover | 2 | −0.40 (−0.68 to −0.12) | 0 | 0.55 | |
| Parallel | 6 | −0.26 (−0.52 to −0.01) | 63.6 | 0.02 | |
| Analysis | 0.02 | ||||
| PP | 5 | −0.51 (−0.77 to −0.25) | 25.7 | 0.25 | |
| ITT | 3 | −0.12 (−0.26 to 0.02) | 0 | 0.79 | |
| Publication year | 0.70 | ||||
| Before 2000 | 3 | −0.42 (−0.81 to −0.03) | 0 | 0.38 | |
| 2000 or later | 5 | −0.28 (−0.51 to −0.05) | 68.5 | 0.01 | |
BMI indicates body mass index; CVD, cardiovascular disease; HDL‐C, high‐density lipoprotein cholesterol; ITT, intention to treat; PP, per protocol.
P for heterogeneity.
P for meta–regression analysis.
Results from fixed‐effect analysis.
Results of Publication Bias Test
| No. of Trials | Pooled Effect (95% CI) mmol/L |
|
| |
|---|---|---|---|---|
| TC | 10 | −0.36 (−0.55 to −0.17) | 0.28 | 0.27 |
| LDL‐C | 7 | −0.34 (−0.57 to −0.11) | 0.37 | 0.54 |
| HDL‐C | 9 | −0.10 (−0.14 to −0.06) | 1.00 | 0.93 |
| TG | 11 | 0.04 (−0.05 to 0.13) | 0.35 | 0.16 |
| Non‐HDL‐C | 8 | −0.30 (−0.50 to −0.10) | 0.27 | 0.42 |
HDL‐C indicates high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
Figure 5Effects of vegetarian diets on weight loss. The meta‐analysis used the WMD in the random‐effects model. Horizontal lines denote 95% CI. A diamond represents the overall estimated effect. WMD, weighted mean difference.